Pradaxa

dabigatran etexilate
Direct Thrombin Inhibitor Boehringer Ingelheim FDA Monitored

Safety Profile Overview

Direct thrombin inhibitor for stroke prevention and VTE. Has a specific reversal agent (idarucizumab). Monitored for GI bleeding.

Generic Name
dabigatran etexilate
Brand Names
Pradaxa
Therapeutic Class
Direct Thrombin Inhibitor
Manufacturer
Boehringer Ingelheim

What Pharma Signal Tracks for Pradaxa

Data Disclaimer: Pharma Signal aggregates data from the FDA Adverse Event Reporting System (FAERS) and other public regulatory sources. FAERS reports do not establish causation. Report counts may reflect prescription volume rather than relative safety. Always consult healthcare professionals for medical decisions.

Get Pradaxa Safety Data via API

One API call returns adverse events, risk scores, recalls, and pharmacovigilance signals for Pradaxa.

curl "https://api.pharma-signal.com/drug/safety/pradaxa" \
  -H "X-API-Key: your_key"

# Returns risk score, adverse event counts,
# serious/death rates, recalls, and signals

Related Safety Intelligence

Pharma Signal provides comparative analysis across therapeutic classes. Compare Pradaxa against other Direct Thrombin Inhibitor drugs, or explore the full manufacturer portfolio for Boehringer Ingelheim.